Alessandro Passardi

33PUBLICATIONS
146CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsPredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jan 08, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Veronica Conca, Daniele Rossini, Carlotta Antoniotti

|Oct 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Carlo Signorelli, Michele Basso, Maria Alessandra Calegari

|Jun 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

|Apr 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

Roberto Moretto, Marco Maria Germani, Martina Carullo

|Dec 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

Carlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone

|Nov 07, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.

Roberto Moretto, Daniele Rossini, Sabina Murgioni

Pageof 6

Frequent Collaborators

7 joint publications

Emanuela Scarpi

7 joint publications

Chiara Cremolini

6 joint publications

Filippo Pietrantonio

6 joint publications

Alessandro Bittoni